51,250 Zoetis Inc. $ZTS Shares Purchased by Heathbridge Capital Management Ltd.

Heathbridge Capital Management Ltd. lifted its holdings in Zoetis Inc. (NYSE:ZTS) by 34.0% during the third quarter, Holdings Channel reports. The fund owned 201,975 shares of the company’s stock after buying an additional 51,250 shares during the quarter. Zoetis makes up 4.7% of Heathbridge Capital Management Ltd.’s holdings, making the stock its 12th largest holding. Heathbridge Capital Management Ltd.’s holdings in Zoetis were worth $14,104,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in ZTS. Wealthfront Advisers LLC boosted its position in Zoetis by 80.2% in the 2nd quarter. Wealthfront Advisers LLC now owns 76,113 shares of the company’s stock worth $5,469,000 after purchasing an additional 33,873 shares in the last quarter. Pacer Advisors Inc. increased its position in shares of Zoetis by 16.7% in the first quarter. Pacer Advisors Inc. now owns 165,570 shares of the company’s stock valued at $19,572,000 after buying an additional 23,687 shares in the last quarter. Diamond Hill Capital Management LLC Investment Advisor lifted its holdings in Zoetis by 21.5% during the second quarter. Diamond Hill Capital Management LLC Investment Advisor now owns 3,557,436 shares of the company’s stock valued at $255,637,000 after purchasing an additional 629,974 shares in the last quarter. Swedbank AB grew its position in shares of Zoetis by 9.9% in the first quarter. Swedbank AB now owns 3,004,200 shares of the company’s stock valued at $355,126,000 after purchasing an additional 269,610 shares during the period. Finally, Munich Reinsurance Co Stock Corp in Munich grew its position in shares of Zoetis by 2,448.6% in the first quarter. Munich Reinsurance Co Stock Corp in Munich now owns 23,804 shares of the company’s stock valued at $2,814,000 after purchasing an additional 22,870 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently weighed in on ZTS. Stifel Nicolaus reduced their price target on shares of Zoetis from $85.00 to $80.00 and set a “hold” rating for the company in a research report on Thursday, August 20th. Weiss Ratings raised shares of Zoetis from a “sell (d)” rating to a “sell (d+)” rating in a research note on Thursday, October 29th. Jefferies Financial Group cut Zoetis from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $103.00 to $83.00 in a report on Tuesday, October 20th. Zacks Research upgraded Zoetis from a “strong sell” rating to a “hold” rating in a research report on Monday, October 26th. Finally, BTIG Research dropped coverage on Zoetis in a research note on Friday, October 30th. They issued a “buy” rating on the stock. Six investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $93.79.

Zoetis Trading Up 0.0%

Shares of Zoetis stock opened at $83.19 on Wednesday. The stock has a market cap of $34.38 billion, a P/E ratio of 13.71, a P/E/G ratio of 1.23 and a beta of 0.67. The stock’s 50 day simple moving average is $75.27 and its 200-day simple moving average is $93.22. Zoetis Inc. has a 1-year low of $68.77 and a 1-year high of $132.49. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, beating the consensus estimate of $1.85 by $0.02. Zoetis had a return on equity of 74.89% and a net margin of 27.49%. The firm had revenue of $2.47 billion during the quarter, compared to analysts’ expectations of $2.50 billion. During the same quarter last year, the firm earned $1.76 earnings per share. The business’s revenue for the quarter was down .2% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Analysts predict that Zoetis Inc. will post 6.15 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 1st. Shareholders of record on Friday, October 30th will be paid a dividend of $0.53 per share. The ex-dividend date of this dividend is Friday, October 30th. This represents a $2.12 dividend on an annualized basis and a yield of 2.5%. Zoetis’s payout ratio is 34.93%.

About Zoetis

Zoetis Inc is a global animal health company that develops, manufactures and markets medicines, vaccines, diagnostics, genetic products and related services for animals. Its offerings support the prevention, diagnosis and treatment of disease in both companion animals, including dogs, cats and horses, and livestock such as cattle, swine, poultry and fish.

The company’s product portfolio includes prescription medicines, parasiticides, vaccines, veterinary diagnostics and animal genetics.